Drugs / F18 Fluciclovine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05054400 | Feb 2020 → Aug 2023 | glioblastoma, metastatic malignant neoplasm in the brain | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F18 Fluciclovine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05054400 ↗ |
| Modality | Diagnostic / imaging agent | “radioactive imaging agent” NCT05054400 ↗ |
| Route | Intravenous | “Given by IV” NCT05054400 ↗ |